High court tosses ruling against Merck on osteoporosis drug
Reprints
(Reuters) — The U.S. Supreme Court on Monday threw out a lower court ruling that had revived hundreds of lawsuits accusing Merck & Co. of failing to properly warn patients of debilitating thigh-bone fractures as a result of taking its osteoporosis drug Fosamax.
The nine justices unanimously directed the Philadelphia-based 3rd U.S. Circuit Court of Appeals to reconsider its decision allowing the lawsuits to proceed even though federal officials had rebuffed Merck when the company sought to add a warning to Fosamax's label about the fracture risk.
At issue in the case was whether a pharmaceutical company can be held liable under state laws for failing to warn about a health risk associated with a drug in stances in which the U.S. Food and Drug Administration rejected a company proposal to add a warning label to the medication about the risk.
Fosamax helps prevent and treat osteoporosis, a condition that can lead to bone fractures, in women who have gone through menopause. But it may increase the risk of fractures in the thigh bone or just below the hip joint, often requiring surgical intervention.
Sales of Fosamax, also available as a generic drug, totaled $209 million in 2018, according to Merck.
Read Next
-
Court upholds dismissal of $200M Merck verdict against Gilead
(Reuters) — A U.S. appeals court on Wednesday affirmed a ruling that pharmaceutical company Merck & Co. dishonestly obtained patent rights and was not entitled to collect a $200 million infringement verdict it won against rival Gilead Sciences Inc.
